Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
VJHemOnc was the official media partner of the 2nd SOHO Italy 2020 Virtual Meeting which took place on the 22-24th of September 2020.
This virtual three-day meeting brought together leading SOHO experts and Italian researchers in acute leukemias, MPNs, and MDS, with the aims of consolidating the Italian Hematology-SOHO partnership.
Watch the meeting on-demand below!
Day One
Day one of the meeting featured sessions on acute lymphoblastic leukemia (ALL).
Session I: State of the art in ALL
- ALL: State of the art in MD Anderson Cancer Center: Hagop Kantarjian
- ALL: State of the art in Europe: Giovanni Martinelli
- Optimizing adult and elderly frontline ALL therapy: Role of immunochemotherapy: Elias Jabbour
- ALL: Ph-like and new genetic subtypes and treatment implications: Marina Konopleva
Session II: Novel treatment approaches in ALL
- CAR T-cells therapy: novel generation, fast-off, dual CAR T-cells: Josep-Maria Ribera
- Novel therapeutic strategies on acute leukemia based on synthetic lethality: Andrea Ghelli Luserna di Rorà
Session III: Beyond ALL and near future
- Diagnostic approaches for Ph-like B-ALL: Sergej Konoplev
- Morphology in acute leukemias and hematologic malignancies: Gina Zini
- Monoclonal antibodies: real-life and new combination trials: Cristina Papayannidis
- Novel monoclonal antibodies combinations and near future of ALL in Italy: Francesco Lanza
Day Two
Day two of the meeting featured sessions on acute myeloid leukemia (AML).
Session IV: Individualized treatment in AML
- Integrated transcriptomic and genomic sequencing identifies prognostic constellations of driver mutations in AML and MDS: Illaria Iacobucci
- Proapoptotic pathways in AML: Sara Galimberti
- Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients: Roberto Lemoli
- Assessment of MRD in AML and integrating MRD into treatment: role of new techniques: Francesco Buccisano
Session V: State of the art in AML
- How I treat AML in MD Anderson Cancer Center: Hagop Kantarjian
- Incorporating novel antibodies as target therapies in the treatment of older AML: Farhad Ravandi
- Updates in immunotherapy and FLT3 inhibitors in AML: Naval Daver
- Maintenance in AML – State of the art: Farhad Ravandi
- How I manage elderly AML in MD Anderson Cancer Center: Tapan Kadia
Session VI: AML - Old certainties vs. new frontiers
- Role of allogeneic transplant in novel agents era: Attilio Olivieri
- Role of postSCT maintenance in AML: Alessandra Sperotto
- Environment-mediated drug resistance in AML: Claudio Cerchione
- Phase 4 studies in Spain: Adolfo De La Fuente
Day Three
Day three of the meeting featured sessions on multiple myeloma (MM), lymphoma, chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs), and myelodysplastic disorders (MDS).
Session VII: Managing multiple myeloma in the era of novel agents
- Genetic profiling of multiple myeloma in the novel agents era: Niccolo Bolli
- How I treat smoldering MM: Maria-Victoria Mateos
- How I manage unfit/frail patients: Daniele Derudas
- Importance of imaging in the era of novel agents: Elena Zamagni
Session VIII: Multiple myeloma - novel agents & ASCT vs CAR-T
- Role of autologous transplant in MM in the novel agents era: Maria T. Petrucci
- CAR T-cell therapies in MM: Massimo Martino
- New drugs on the horizon: Francesco Di Raimondo
Session IX: State of the art in multiple myeloma
- Multiple myeloma: state of the art in the USA: Kenneth Anderson
- Multiple myeloma: state of the art in Europe: Claudio Cerchione
- Near future of MM in Europe: Maria-Victoria Mateos
- Near future of MM in the USA: Kenneth Anderson
Session X: State of the art in non-Hodgkin lymphoma
- How I manage DLBCL lymphoma in USA: Peter Martin
- How I manage follicular, mantle cell and marginal lymphoma in Italy: Stefano Luminari
Session XI: Hodgkin lymphoma and the biology of lymphoma
- How I manage Hodgkin disease in the USA: John Leonard
- Challenges and new opportunities to manage Waldenstrom disease in Italy: Alessandra Tedeschi
- Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma: Enrico Derenzini
- Near future of Hodgkin lymphomas: Antonello Pinto
Session XII: Chronic myeloid leukemia
- How I manage CML in Italy: Giuseppe Saglio
- Treatment-free remission where and when?: Michele Malagola
- TFR: lights and shadows: Elisabetta Abruzzese
Session XIII: New insights in MPNs
- Management of myeloproliferative neoplasms: Srdan Verstovsek
Session XIV: State of the art in MDS
- State of the art in the USA – Emerging frontline HMA based regimens: Guillermo Garcia-Manero
- Patient-centred approach for the treatment of MDS: importance of quality of life: Esther Oliva
